Leerink Partnrs Has Pessimistic Outlook of ABT Q3 Earnings

Abbott Laboratories (NYSE:ABT) – Investment analysts at Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for Abbott Laboratories in a research note issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now anticipates that the healthcare product maker will post earnings of $1.29 per share for the quarter, down from their prior forecast of $1.30. The consensus estimate for Abbott Laboratories’ current full-year earnings is $5.14 per share. Leerink Partnrs also issued estimates for Abbott Laboratories’ FY2025 earnings at $5.13 EPS, FY2026 earnings at $5.65 EPS, FY2027 earnings at $6.23 EPS, FY2028 earnings at $6.84 EPS and FY2029 earnings at $7.50 EPS.

A number of other research firms also recently weighed in on ABT. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. Wells Fargo & Company dropped their price objective on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Weiss Ratings reiterated a “buy (b)” rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. The Goldman Sachs Group upped their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Finally, Raymond James Financial dropped their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $146.17.

Abbott Laboratories Trading Down 2.9%

ABT stock opened at $129.35 on Wednesday. The company has a market cap of $225.13 billion, a P/E ratio of 16.21, a PEG ratio of 2.53 and a beta of 0.69. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The business has a fifty day moving average of $132.59 and a 200-day moving average of $131.60.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. The company had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ABT. Norges Bank acquired a new position in shares of Abbott Laboratories during the second quarter worth about $3,026,180,000. Nuveen LLC acquired a new position in shares of Abbott Laboratories during the first quarter worth about $1,658,180,000. Laurel Wealth Advisors LLC boosted its position in shares of Abbott Laboratories by 13,347.0% during the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock worth $823,804,000 after buying an additional 6,011,891 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Abbott Laboratories by 29.2% during the first quarter. Goldman Sachs Group Inc. now owns 15,985,797 shares of the healthcare product maker’s stock worth $2,120,516,000 after buying an additional 3,616,471 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of Abbott Laboratories by 12.8% during the first quarter. Wellington Management Group LLP now owns 29,763,415 shares of the healthcare product maker’s stock worth $3,948,117,000 after buying an additional 3,371,113 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s payout ratio is presently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.